H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ)

July 7, 2026 7:04 AM

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $38.00 price target on LENZ Therapeutics Inc (NASDAQ: LENZ).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found